{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:28:07Z","timestamp":1773901687866,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["26860346"],"award-info":[{"award-number":["26860346"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17K08911"],"award-info":[{"award-number":["17K08911"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s12185-020-02972-0","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T19:03:41Z","timestamp":1598987021000},"page":"841-850","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Use of unapproved or off-label drugs in Japan for the treatment of graft-versus-host disease and post-transplant viral infection"],"prefix":"10.1007","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6092-3948","authenticated-orcid":false,"given":"Yachiyo","family":"Kuwatsuka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Inamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuho","family":"Najima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Ikegame","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Eto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiyasu","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Ichinohe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Miyamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"key":"2972_CR1","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMra052638","volume":"354","author":"EA Copelan","year":"2006","unstructured":"Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813\u201326.","journal-title":"N Engl J Med"},{"key":"2972_CR2","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/cpt.192","volume":"98","author":"AF Poirier","year":"2015","unstructured":"Poirier AF. Closing the drug lag for new drug submission and review in Japan: an industry perspective. Clin Pharmacol Ther. 2015;98:486\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"2972_CR3","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1007\/s10637-018-0612-y","volume":"37","author":"H Nakayama","year":"2019","unstructured":"Nakayama H, Matsumaru N, Tsukamoto K. The drug lag and associated factors for orphan anticancer drugs in Japan compared to the United States. Invest New Drugs. 2019;37:1086\u201393.","journal-title":"Invest New Drugs"},{"key":"2972_CR4","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1002\/jcph.951","volume":"57","author":"S Kogure","year":"2017","unstructured":"Kogure S, Koyama N, Hidaka S. Utilization of the bridging strategy for the development of new drugs in oncology to avoid drug lag. J Clin Pharmacol. 2017;57:1479\u201390.","journal-title":"J Clin Pharmacol"},{"key":"2972_CR5","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s12185-011-0817-8","volume":"93","author":"M Iida","year":"2011","unstructured":"Iida M, Fukuda T, Ikegame K, Yoshihara S, Ogawa H, Taniguchi S, et al. Use of mycophenolate mofetil in patients received allogeneic hematopoietic stem cell transplantation in Japan. Int J Hematol. 2011;93:523\u201331.","journal-title":"Int J Hematol"},{"key":"2972_CR6","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1111\/ctr.12405","volume":"28","author":"M Iida","year":"2014","unstructured":"Iida M, Fukuda T, Uchida N, Murata M, Aotsuka N, Minagawa K, et al. Mycophenolate mofetil use after unrelated hematopoietic stem cell transplantation for prophylaxis and treatment of graft-vs.-host disease in adult patients in Japan. Clin Transplant. 2014;28:980\u20139.","journal-title":"Clin Transplant"},{"key":"2972_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","volume":"103","author":"Y Atsuta","year":"2016","unstructured":"Atsuta Y. Introduction of transplant registry unified management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol. 2016;103:3\u201310.","journal-title":"Int J Hematol"},{"key":"2972_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12185-015-1907-9","volume":"103","author":"J Kanda","year":"2016","unstructured":"Kanda J. Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation. Int J Hematol. 2016;103:11\u20139.","journal-title":"Int J Hematol"},{"key":"2972_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s12185-015-1896-8","volume":"103","author":"Y Kuwatsuka","year":"2016","unstructured":"Kuwatsuka Y. Quality control and assurance in hematopoietic stem cell transplantation data registries in Japan and other countries. Int J Hematol. 2016;103:20\u20134.","journal-title":"Int J Hematol"},{"key":"2972_CR10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/BF03006932","volume":"86","author":"Y Atsuta","year":"2007","unstructured":"Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A, et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP system. Int J Hematol. 2007;86:269\u201374.","journal-title":"Int J Hematol"},{"key":"2972_CR11","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. Consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15:825\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"2972_CR12","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S0889-8588(05)70111-8","volume":"13","author":"ME Flowers","year":"1999","unstructured":"Flowers ME, Kansu E, Sullivan KM. Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am. 1999;13:1091\u2013112.","journal-title":"Hematol Oncol Clin North Am"},{"key":"2972_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","volume":"47","author":"AC Allison","year":"2000","unstructured":"Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85\u2013118.","journal-title":"Immunopharmacology"},{"key":"2972_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s12185-012-1086-x","volume":"96","author":"K Minagawa","year":"2012","unstructured":"Minagawa K, Yamamori M, Katayama Y, Matsui T. Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis. Int J Hematol. 2012;96:10\u201325.","journal-title":"Int J Hematol"},{"key":"2972_CR15","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/bmt.2017.116","volume":"52","author":"S Terakura","year":"2017","unstructured":"Terakura S, Kuwatsuka Y, Yamasaki S, Wake A, Kanda J, Inamoto Y, et al. GvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemia. Bone Marrow Transpl. 2017;52:1261\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"2972_CR16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41375-019-0534-5","volume":"34","author":"J Kanda","year":"2020","unstructured":"Kanda J, Hayashi H, Ruggeri A, Kimura F, Volt F, Takahashi S, et al. Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord\/ALWP-EBMT and JSHCT\/JDCHCT collaborative study. Leukemia. 2020;34:128\u201337.","journal-title":"Leukemia"},{"key":"2972_CR17","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/bmt.2016.265","volume":"52","author":"YB Chen","year":"2017","unstructured":"Chen YB, Wang T, Hemmer MT, Brady C, Couriel DR, Alousi A, et al. GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes. Bone Marrow Transpl. 2017;52:400\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"2972_CR18","unstructured":"Ministry of Health Labour and Welfare. https:\/\/kouseikyoku.mhlw.go.jp\/kantoshinetsu\/gyomu\/gyomu\/hoken_kikan\/tsuchi\/310228_003.pdf. Accessed in 2019."},{"key":"2972_CR19","unstructured":"Ministry of Health Labour and Welfare. https:\/\/www.mhlw.go.jp\/stf\/shingi2\/0000205197_00005.html Accessed in 2019."},{"key":"2972_CR20","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s12185-019-02601-5","volume":"109","author":"N Kawashima","year":"2019","unstructured":"Kawashima N, Iida M, Suzuki R, Fukuda T, Atsuta Y, Hashii Y, et al. Prophylaxis and treatment with mycophenolate mofetil in children with graft-versus-host disease undergoing allogeneic hematopoietic stem cell transplantation: a nationwide survey in Japan. Int J Hematol. 2019;109:491\u20138.","journal-title":"Int J Hematol"},{"key":"2972_CR21","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s00277-018-3385-7","volume":"97","author":"M Tamaki","year":"2018","unstructured":"Tamaki M, Nakasone H, Misaki Y, Yoshimura K, Gomyo A, Hayakawa J, et al. Outcome of gastrointestinal graft-versus-host disease according to the treatment response. Ann Hematol. 2018;97:1951\u201360.","journal-title":"Ann Hematol"},{"key":"2972_CR22","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1182\/blood-2006-05-021139","volume":"109","author":"DM Hockenbery","year":"2007","unstructured":"Hockenbery DM, Cruickshank S, Rodell TC, Gooley T, Schuening F, Rowley S, et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood. 2007;109:4557\u2013633.","journal-title":"Blood"},{"key":"2972_CR23","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.2169\/internalmedicine.53.1858","volume":"53","author":"S Takashima","year":"2014","unstructured":"Takashima S, Eto T, Shiratsuchi M, Hidaka M, Mori Y, Kato K, et al. The use of oral beclomethasone dipropionate in the treatment of gastrointestinal graft-versus-host disease: the experience of the Fukuoka blood and marrow transplantation (BMT) group. Intern Med. 2014;53:1315\u201320.","journal-title":"Intern Med"},{"key":"2972_CR24","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.bbmt.2017.05.001","volume":"23","author":"FF Yalniz","year":"2017","unstructured":"Yalniz FF, Hefazi M, McCullough K, Litzow MR, Hogan WJ, Wolf R, et al. Safety and efficacy of infliximab therapy in the setting of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transpl. 2017;23:1478\u201384.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2972_CR25","first-page":"1352","volume":"89","author":"F Patriarca","year":"2004","unstructured":"Patriarca F, Sperotto A, Damiani D, Morreale G, Bonifazi F, Olivieri A, et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica. 2004;89:1352\u20139.","journal-title":"Haematologica"},{"key":"2972_CR26","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s41409-018-0099-3","volume":"53","author":"M Nygaard","year":"2018","unstructured":"Nygaard M, Andersen NS, Moser CE, Olesen G, Schjodt IM, Heilmann C, et al. Evaluation of infliximab as second-line treatment of acute graft versus host disease-validating response on day 7 and 28 as predictors of survival. Bone Marrow Transpl. 2018;53:844\u201351.","journal-title":"Bone Marrow Transpl"},{"key":"2972_CR27","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1182\/blood-2007-09-112987","volume":"111","author":"JE Levine","year":"2008","unstructured":"Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ, et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood. 2008;111:2470\u20135.","journal-title":"Blood"},{"key":"2972_CR28","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.bbmt.2018.11.017","volume":"25","author":"M Faraci","year":"2019","unstructured":"Faraci M, Calevo MG, Giardino S, Leoni M, Ricci E, Castagnola E, et al. Etanercept as treatment of steroid-refractory acute graft-versus-host disease in pediatric patients. Biol Blood Marrow Transpl. 2019;25:743\u20138.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2972_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/ajh.20752","volume":"82","author":"A Busca","year":"2007","unstructured":"Busca A, Locatelli F, Marmont F, Ceretto C, Falda M. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2007;82:45\u201352.","journal-title":"Am J Hematol"},{"key":"2972_CR30","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.2169\/internalmedicine.46.1913","volume":"46","author":"T Takeuchi","year":"2007","unstructured":"Takeuchi T. Treatment of inflammatory immunologic disease 3. Anti-TNF therapy in rheumatoid arthritis. Intern Med. 2007;46:1311\u20132.","journal-title":"Intern Med"},{"key":"2972_CR31","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s12185-010-0657-y","volume":"92","author":"M Asakura","year":"2010","unstructured":"Asakura M, Ikegame K, Yoshihara S, Taniguchi S, Mori T, Etoh T, et al. Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor. Int J Hematol. 2010;92:351\u20139.","journal-title":"Int J Hematol"},{"key":"2972_CR32","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/sj.bmt.1703083","volume":"28","author":"V Runde","year":"2001","unstructured":"Runde V, Ross S, Trenschel R, Lagemann E, Basu O, Renzing-Kohler K, et al. Adenoviral infection after allogeneic stem cell transplantation (SCT): report on 130 patients from a single SCT unit involved in a prospective multi center surveillance study. Bone Marrow Transpl. 2001;28:51\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"2972_CR33","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood-2002-02-0377","volume":"100","author":"S Chakrabarti","year":"2002","unstructured":"Chakrabarti S, Mautner V, Osman H, Collingham KE, Fegan CD, Klapper PE, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood. 2002;100:1619\u201327.","journal-title":"Blood"},{"key":"2972_CR34","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.bbmt.2011.09.007","volume":"18","author":"DF Florescu","year":"2012","unstructured":"Florescu DF, Pergam SA, Neely MN, Qiu F, Johnston C, Way S, et al. Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Biol Blood Marrow Transpl. 2012;18:731\u20138.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2972_CR35","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jcv.2017.09.013","volume":"96","author":"ID Ramsay","year":"2017","unstructured":"Ramsay ID, Attwood C, Irish D, Griffiths PD, Kyriakou C, Lowe DM. Disseminated adenovirus infection after allogeneic stem cell transplant and the potential role of brincidofovir\u2014case series and 10 year experience of management in an adult transplant cohort. J Clin Virol. 2017;96:73\u20139.","journal-title":"J Clin Virol"},{"key":"2972_CR36","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.bbmt.2016.12.621","volume":"23","author":"MS Grimley","year":"2017","unstructured":"Grimley MS, Chemaly RF, Englund JA, Kurtzberg J, Chittick G, Brundage TM, et al. Brincidofovir for asymptomatic adenovirus viremia in pediatric and adult allogeneic hematopoietic cell transplant recipients: a randomized placebo-controlled phase II trial. Biol Blood Marrow Transpl. 2017;23:512\u201321.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2972_CR37","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1007\/s10147-015-0825-4","volume":"20","author":"H Maeda","year":"2015","unstructured":"Maeda H, Kurokawa T. Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan? Int J Clin Oncol. 2015;20:1072\u201380.","journal-title":"Int J Clin Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02972-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-020-02972-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02972-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:28:11Z","timestamp":1630456091000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-020-02972-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2972"],"URL":"https:\/\/doi.org\/10.1007\/s12185-020-02972-0","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,1]]},"assertion":[{"value":"19 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"YK reports grants from Japan Society for the Promotion of Science, during the conduct of the study; YA reports personal fees from Astellas Pharma Inc., Mochida Pharmaceutical Co., Ltd., Meiji Seika Pharma Co, Ltd., CHUGAI PHARMACEUTICAL CO., LTD., Kyowa Kirin Co., Ltd, Janssen Pharmaceutical K.K., outside the submitted work; AH reports grants and personal fees from Ono Pharmaceutical, personal fees from Astellas Pharma, Abbvie, Nippon Boehringer Ingelheim, Kissei Pharmaceutical, Pfizer, Nippon Shinyaku, Chugai Pharmaceutical, Taiho Pharmaceutical, Torii Pharmaceutical, Sumitomo Dainippon Pharma, Teijin Pharma, Fuji Pharma, Japan Tabacco, HEALIOS K.K, Life Science Institute, Inc., Novartis Japan, outside the submitted work; NU reports and personal fees from Chugai Pharmaceutical Co., Ltd., Astellas Pharma Inc., Otsuka Pharmaceeutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., and Novartis Pharma Inc, outside the submitted work; YI reports personal fees from Kyowa Kirin Co., Ltd, Astellas Pharma Inc., Sumitomo Dainippon Pharma Co., Ltd., Novartis, outside the submitted work; YN received personal fees from Pfizer; YO reports personal fees from Pfizer Japan, Astellas Pharma, Novartis Pharma, Kyowa Hakko Kirin, outside the submitted work; TI reports grants from Chugai Pharmaceutical Co., Pfizer, Astellas Pharma, Zenyaku Kogyo Co., and personal fees from Novartis, outside the submitted work; SO reports grants from Asahi Kasei Pharma, Astellas, Eisai, Otsuka, Ono, Kyowa Kirin, Sanofi, Shionogi, Daiichi Sankyo, Takeda, Dainihon Sumitomo, Chugai, Teijin Pharma, Novartis, Mochida, JCR Pharma, Pfizer, personal fees from Astellas, Eisai, Otsuka, Ono, Kyowa Kirin, Sanofi, Daiichi Sankyo, Takeda, Chugai, Nihon Shinyaku, Novartis, BMS, Mochida, JCR Pharma, Pfizer, outside the submitted work; KM reports personal fees from Bristol-Myers Squibb, Novartis, Pfizer, Otsuka, Takeda, Kyowa-Hakko Kirin, Chugai, Astellas Pharmaceuticals, Celgene, Daiichi-Sankyo, Mochida, outside the submitted work. The other authors declare no competing financial interests regarding this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}